Related Experiment Video
Updated: Apr 16, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
[Biosimilars--opportunity or threat?]
1Klinika Reumatologii i Chorób Wewnetrznych, Uniwersytet Medyczny im. Piastów Slaskich we Wrocławiu. jurekswierkot0@poczta.onet.pl
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|March 18, 2015
Summary
Biosimilars are high-quality, safe, and effective alternatives to reference biologic medicines. As patents expire, biosimilar monoclonal antibodies will increase patient access to biological treatments.
Area of Science:
- Biopharmaceutical Science
- Regulatory Affairs
Context:
- Patent expiries for biological drugs, including monoclonal antibodies, are imminent.
- Growing global interest in biosimilars necessitates a clear understanding of their regulatory status and characteristics.
Purpose:
- To consolidate key information regarding biosimilar medicines.
- To differentiate biosimilars from counterfeit or imitation products.
- To highlight the regulatory requirements for biosimilar approval.
Summary:
- Biosimilars are highly similar to approved reference biotherapeutic products in terms of quality, efficacy, and safety.
- Regulatory bodies like the European Medicines Agency (EMA) and FDA enforce stringent standards for biosimilar approval, including immunogenicity.
- Ongoing clinical trials are assessing the interchangeability of innovative and biosimilar drugs, though regulatory frameworks are still evolving.
Impact:
- Increased availability of biological treatments for patients, particularly in rheumatology and gastroenterology, is anticipated.
- Biosimilars offer potential for cost savings and expanded patient access to advanced therapies.
- Clearer regulatory guidelines will foster greater confidence and adoption of biosimilar medicines.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
01:16Bioequivalence: Overview
2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
01:13Bioequivalence studies: Biowaivers
414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
224
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
224
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
250
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
250
01:26Pharmaceutical Equivalents
267
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
267